Diagnostics

NUS researchers develop revolutionary technology to unravel complex protein interactions that could transform cancer diagnostics

Scalable and adaptable, TETRIS captures the diversity of protein interactions on site to inform accurate cancer diagnoses, enabling the personalisation...

GE HealthCare announces FDA approval of Flyrcado (flurpiridaz F 18) injection PET radiotracer for enhanced diagnosis of coronary artery disease

GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary...

Cardiex Announces Publication of Breakthrough Study Validating Noninvasive Fingertip Photoplethysmography (PPG) for Central Aortic Pressure Waveform Analysis

SYDNEY, Sept. 26, 2024 /PRNewswire/ -- Cardiex Limited (ASX: CDX), a global health technology company focused on cardiovascular diagnostics and arterial...

LUNAPHORE PARTNERS WITH DISCOVERY LIFE SCIENCES TO BRING INNOVATIVE SPATIAL BIOLOGY SOLUTIONS TO CLINICAL RESEARCH

MINNEAPOLIS , Sept. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that one of its spatial biology brands, Lunaphore,...

New Data Reveals BD’s Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion

FRANKLIN LAKES, N.J., Sept. 26, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company,...

Mediwhale Secures $12 Million in Series A2 Funding to Drive Global Leadership in Cardiovascular and Metabolic Disease Management

SEOUL, South Korea, Sept. 25, 2024 /PRNewswire/ -- Mediwhale, the AI-powered health diagnostics company, announced $12 million series A2 investments. This funding...

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests

New investment supports DxA's mission to advance the development of scalable and universally accessible diagnostics.Blood tests will be key to...

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development...

error: Content is protected !!